Bausch + Lomb Says FDA Supportive In Principle Of Initial Study Design For Oral Dry AMD Drug BL1243, Expects 2027 Start
Share
Why It Matters
Bausch + Lomb got encouragement from the FDA about a new dry eye medicine. Watch how the company moves forward to see if the drug might work.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.